{"url_path":"/sec/aidx/10-q/2026/item-1","section_key":"item-1","section_title":"Item 1 LEGAL PROCEEDINGS.**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-20","source_url":"https://www.sec.gov/Archives/edgar/data/1139685/0001213900-26-059542-index.html","accession_number":"0001213900-26-059542","cik":"0001139685","ticker":"AIDX","issuer_name":"20/20 Biolabs, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1139685/0001213900-26-059542-index.html","primary_entity_key":"0001139685","primary_entity_name":"20/20 Biolabs, Inc."},"word_count":82,"has_tables":true,"body_markdown":"** **\n\n**ITEM 1. LEGAL PROCEEDINGS.**\n\n \n\nFrom time to time, we may become involved in various\nlawsuits and legal proceedings, which arise in the ordinary course of business. However, litigation is subject to inherent uncertainties,\nand an adverse result in these, or other matters, may arise from time to time that may harm our business. We are currently not aware of\nany such legal proceedings or claims that we believe will have a material adverse effect on our business, financial condition or operating\nresults."}